Introduction {#section1-0891988715606229}
============

Posterior cortical atrophy (PCA) is a neurodegenerative syndrome characterized by progressive impairment of visual functions in the absence of visual acuity deficits and a pattern of atrophy involving parietal, occipital, and occipitotemporal cortex.^[@bibr1-0891988715606229],[@bibr2-0891988715606229]^ Posterior cortical atrophy is considered the most common atypical presentation of Alzheimer disease (AD).^[@bibr3-0891988715606229][@bibr4-0891988715606229]-[@bibr5-0891988715606229]^ Contrary to typical AD, episodic memory and insight are relatively preserved in the initial stages of the disease, while reading, object recognition, navigational orientation, and praxis are early affected. Other posterior symptoms, such as elements of Balint (simultanagnosia, optic ataxia, and ocular apraxia) and Gertsmann syndrome (agraphia, acalculia, finger agnosia, and right--left confusion), are also frequent. The syndrome is usually caused by AD pathology and less frequently by dementia with Lewy bodies (DLB), corticobasal degeneration, prion associated disease, and subcortical gliosis.^[@bibr3-0891988715606229],[@bibr6-0891988715606229][@bibr7-0891988715606229]-[@bibr8-0891988715606229]^

A number of studies have focused on characterizing the cognitive and language profile, brain atrophy pattern, genetics, and possible therapeutic strategies in PCA^[@bibr6-0891988715606229],[@bibr9-0891988715606229][@bibr10-0891988715606229][@bibr11-0891988715606229][@bibr12-0891988715606229][@bibr13-0891988715606229][@bibr14-0891988715606229][@bibr15-0891988715606229][@bibr16-0891988715606229]-[@bibr17-0891988715606229]^; however, little is known about its neuropsychiatric profile.^[@bibr18-0891988715606229]^ Neuropsychiatric symptoms (NPS) are variably associated with the severity of cognitive decline in a number of neurodegenerative conditions^[@bibr19-0891988715606229][@bibr20-0891988715606229][@bibr21-0891988715606229]-[@bibr22-0891988715606229]^ and have an impact in patient's quality of life, caregiver distress, and likelihood of institutionalization. By improving our understanding of NPS in PCA, we aim to contribute to (1) improving diagnosis and prognosis, (2) providing a more comprehensive picture of the evolution of clinical symptoms and associated problems across the course of the disease, and (3) planning and delivering effective support and psychoeducational training for caregivers.

The main goal of the present study is to characterize the neuropsychiatric profile of PCA. We aim to do so by (1) describing the differences in the NPS between PCA and AD and (2) investigating the relationship between NPS, age at onset, and cognitive impairment in PCA.

Methods {#section2-0891988715606229}
=======

Participants were 28 patients with PCA and a convenience control sample of 34 patients with typical AD diagnosed at the Memory Disorders Unit of the Hospital Virgen del Rocio. Patients with PCA fulfilled current available clinical criteria^[@bibr6-0891988715606229]^ comprising insidious onset and gradual progression, presentation of disabling visual complaints in the absence of significant primary ocular disease explaining the symptoms, and relative preservation of anterograde memory and insight early in the disorder. Patients with typical AD met diagnosis criteria for probable AD.^[@bibr23-0891988715606229],[@bibr24-0891988715606229]^ Exclusion criteria included severe global cognitive impairment (defined by patient inability to undertake the cognitive assessment) and significant ischemic burden (scoring 1 or more on the Fazekas scale^[@bibr25-0891988715606229]^). The local institutional review board approved this protocol.

In addition to standard demographic and clinical data, all patients and their relatives completed the 12-item Neuropsychiatric Inventory (NPI), a questionnaire that evaluates the presence, frequency, and severity of 10 different behavioral areas (delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and abnormal motor behavior) and 2 neurovegetative areas (sleep and nighttime behavior disorders and appetite and eating disorders) over the past month.^[@bibr26-0891988715606229]^ For the purpose of this study, only presence and not frequency or severity of NPS has been examined. Neuropsychological assessment consisted of tests of global cognitive function (Mini-Mental State Examination \[MMSE\]), executive function (phonemic and semantic verbal fluency^[@bibr27-0891988715606229]^), memory (word list immediate recall and recognition^[@bibr28-0891988715606229]^), language (Boston Naming Test^[@bibr29-0891988715606229]^ and verbal/written comprehension^[@bibr27-0891988715606229]^), and visuoperceptual and spatial function (Visual Object and Space Perception Battery).^[@bibr30-0891988715606229]^

Three of the patients with PCA received a diagnosis of probable DLB^[@bibr31-0891988715606229]^ at follow-up, more than 4 years after initial diagnosis and after having developed fluctuations, visual hallucinations (VH) or parkinsonism, and presenting low dopamine transporter uptake in basal ganglia demonstrated by DAT SPECT scan (^123^I-FP-CIT DATscan, GE Healthcare; patients present with 2 core features and a suggestive feature or one core feature and a suggestive feature). The NPI values of these individuals were collected within 6 months of the date of the SPECT. As the aim of the present study was to examine the neuropsychiatry of the PCA spectrum, these patients remained included in the set, avoiding the potential bias that would result from their exclusion in the overall analysis.

Chi-square or Fisher exact test was used for the analysis of dichotomous variables, while unpaired *t* test and Mann Whitney *U* were used for continuous variables depending whether or not they followed a normal distribution. A Spearman rank correlation coefficient was used to assess the relationship between cognitive performances and the occurrence of NPS.

Results {#section3-0891988715606229}
=======

The demographic and clinical characteristics of the PCA and AD groups, as well as neuropsychological performances of the PCA group, are summarized in [Table 1](#table1-0891988715606229){ref-type="table"}. Samples were matched for age, illness duration (from symptoms onset), and severity of cognitive decline (MMSE). There were no differences in the proportion of patients receiving related medication (cholinesterase inhibitors, antipsychotics, antidepressants, and benzodiazepines).

###### 

Demographic and Clinical Characteristics of the Study Groups.^a^

![](10.1177_0891988715606229-table1)

                                             PCA (n = 28)         AD (n = 34 )         *P* Value
  ------------------------------------------ -------------------- -------------------- -----------
  Gender, female, n (%)                      15 (53)              22 (64)              .37^b^
  Age, y, mean ± SD                          64 ± 6.7 \[54-79\]   66 ± 6.9 \[53-79\]   .16^c^
  Disease duration, y, mean ± SD \[range\]   4 ± 2.8 \[1-13\]     4 ± 2.4 \[1-10\]     .47^d^
  Age at onset, y, mean ± SD \[range\]       59 ± 7.4 \[42-75\]   62 ± 8.5 \[43-78\]   .14^c^
  Percentage onset ≤ 65 years                82% (23/28)          61% (21/34)          .079^b^
  Cholinesterase inhibitors, n (%)           26 (92)              31 (91)              .80^b^
  Anti-psychotics, n (%)                     1 (3)                0                    .45^e^
  Antidepressants, n (%)                     6 (21)               3 (8)                .27^e^
  Benzodiazepines, n (%)                     1 (3)                0                    .45^e^
  MMSE (max. 30), mean ± SD                  13 ± 4.5 \[5-22\]    14 ± 3.8 \[6-22\]    .57^c^
  Neuropsychology data                                                                 
   Phonemic fluency                          8 ± 7.4              --                   
   Semantic fluency                          3 ± 3.5              --                   
   Word list immediate (WMS-R)               6 ± 6.2              --                   
   Word list recognition (WMS-R)             10 ± 5.3             --                   
   Naming (Brief BNT)                        8 ± 3.9              --                   
   Comprehension: spoken sentences           10 ± 5.9             --                   
   Comprehension: written sentences          2 ± 4.2              --                   
   VOSP Incomplete letters                   2 ± 4.6              --                   
   VOSP Dot counting                         3 ± 3.3              --                   

Abbreviations: MMSE, Mini-Mental State Examination; WMS-R, Wechsler Memory Scale Revised (Wechsler^[@bibr28-0891988715606229]^); BNT, Boston Naming Test (Goodglass et al^[@bibr29-0891988715606229]^); VOSP, Visual Object and Space Perception Battery (Warrington & James^[@bibr30-0891988715606229]^); PCA, posterior cortical atrophy; AD, Alzheimer disease; SD, standard deviation.

^a^Values expressed as mean ± SD or percentage as indicated.

^b^Pearson χ^2^ test

^c^Unpaired *t* test.

^d^Mann Whitney *U* test.

^e^Fisher exact test.

Chi-square tests revealed no differences between the PCA and the AD groups in the presence of each symptom on the NPI (see [Figure 1](#fig1-0891988715606229){ref-type="fig"}). The most common symptoms were depression (64% PCA vs 61% AD, *P* = .83), irritability (50% PCA vs 64% AD, *P* = .24), anxiety (42% PCA vs 55% AD, *P =* .30), and apathy (42% PCA, vs 64% AD, *P* = .085). No differences were found in the presence of delusions or hallucinations between PCA and AD (delusions: 7 \[25%\] PCA vs 6 \[17%\] AD, *P* = .47; hallucinations: 3 \[10%\] PCA vs 3 \[8%\] AD, *P* = .80). Two (7%) patients in the PCA group but no one in the AD group presented with auditory hallucinations (AH), always accompanied by VH; these patients were 2 of the 3 individuals in the PCA group who were diagnosed with DLB.

![Prevalence of neuropsychiatric symptoms in patients with PCA and AD. AMB, indicates abnormal motor behavior; NBD, nightime behavioral disturbances; PCA, posterior cortical atrophy; AD, Alzheimer disease. Symptoms are ordered from more to less frequent in the PCA group.](10.1177_0891988715606229-fig1){#fig1-0891988715606229}

To investigate the relationship between the age of onset and NPS, the PCA and AD sampled were split into early-onset (≤65 years) and late-onset (\>65 years) subgroups (see [Figure 2](#fig2-0891988715606229){ref-type="fig"}). In the PCA group, 47% (11 of 23) of the early-onset and 20% (1 of 5) of the late-onset patients presented anxiety, while the proportion of patients with anxiety in the AD group was 71% (15 of 21) in the early-onset and 30% (4 of 13) in the late-onset group. Levels of anxiety were significantly higher in the early-onset than late-onset AD subgroup (71% vs 30%, *P* = .02). Presence of anxiety did not differ between the PCA subgroups (47% vs 20%, *P =* .35) or between early-onset PCA and early-onset AD (47% vs 71%, *P* = .11). There were no other significant differences between early-onset and late-onset PCA or AD subgroups in the occurrence of any other NPS.

![Relationship between age at onset and anxiety in PCA and AD. \*Statistically significant difference, *P* = .020. PCA indicates posterior cortical atrophy; AD, Alzheimer disease.](10.1177_0891988715606229-fig2){#fig2-0891988715606229}

Spearman correlation analysis yielded a significant inverse relationship between naming and the occurrence of delusions and agitation in PCA (delusions, *r* = −.48, *P* = .009; agitation, *r* = −.41, *P* = .029). There were no other significant correlations between NPS and neuropsychological test scores.

Discussion {#section4-0891988715606229}
==========

This study compared the neuropsychiatric profile of PCA and typical AD. The overall results suggest a similar pattern of neuropsychiatric disturbance in PCA and AD, with a trend toward less apathy in the PCA group. There were no significant differences between both groups in the presence of NPS. The 4 most frequently occurring symptoms in our PCA sample were depression, irritability, apathy, and anxiety. These 4 features were also the 4 most common NPS in the AD control sample and are all in the top 5 most frequently occurring NPS averaging across 13 previous studies of neuropsychiatric features of AD (see [Table 2](#table2-0891988715606229){ref-type="table"}).

###### 

Percentage of Participants Showing Individual NPS in the Current Study, the Previous Study of PCA, and 14 Previous Studies Using the NPI in AD.^a^

![](10.1177_0891988715606229-table2)

                                                     Current study   Isella et al (2014)   Suarez- Gonzalez et al, (2014)   Van Vliet et al, (2012)^[@bibr33-0891988715606229]^   Toyota et al, (2007)^[@bibr34-0891988715606229]^   Zhang et al, (2012)^[@bibr35-0891988715606229]^   D'Onofrio et al, (2012)^[@bibr36-0891988715606229]^   Karttunen et al, (2011)^[@bibr37-0891988715606229]^   Yener et al, (2009)^[@bibr38-0891988715606229]^   Del Prete et al, (2009)^[@bibr39-0891988715606229]^   Hsieh et al, (2009)^[@bibr40-0891988715606229]^   Caputo et al, (2008)^[@bibr41-0891988715606229]^   Fuh et al, (2005)^[@bibr42-0891988715606229]^   Srikanth et al, (2005)^[@bibr43-0891988715606229]^   Senanarong et al, (2005)^[@bibr44-0891988715606229]^   Mean% showing NPS   Range% showing NPS   Rank order% showing NPS   Mean % (selected studies^b^)   Range % (selected studies^b^)                                                      
  -------------------------------------- ------ ---- --------------- --------------------- -------------------------------- ----------------------------------------------------- -------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ----------------------------------------------- ---------------------------------------------------- ------------------------------------------------------ ------------------- -------------------- ------------------------- ------------------------------ ------------------------------- ----- ---- ---- ---- ------- ---- ---- ----------- --
  Diagnosis                              PCA    AD   PCA             AD                    AD                               AD                                                    AD                                                 AD                                                AD                                                    AD                                                    AD                                                AD                                                    AD                                                AD                                                 AD                                              AD                                                   AD                                                     AD                  AD                   AD                        AD                             AD                              AD    AD   AD                                      
  N                                      28     34   20              20                    85                               79                                                    68                                                 46                                                261                                                   46                                                    166                                               240                                                   81                                                159                                                78                                              94                                                   45                                                     53                  25                   690                       188                            107                             25    44   73                                      
  MMSE                                   Mean   13   14              24                    25                               16                                                    19                                                 19                                                17                                                    19                                                    23                                                14                                                    --                                                --                                                 --                                              ^c^-                                                 ^d^-                                                   ^e^-                19                   16                        14                             --                              --    --   14   18                                 
  SD                                     5      4    3               2                     6                                7                                                     4                                                  8                                                 6                                                     2                                                     5                                                 --                                                    --                                                --                                                 --                                              --                                                   --                                                     4                   6                    6                         --                             --                              --    5    6                                       
  CDR                                    --     --   \-              --                    --                               --                                                    --                                                 --                                                --                                                    --                                                    --                                                --                                                    0.5                                               (1-2)                                              --                                              --                                                   --                                                     --                  --                   --                        1                              2                               3     --   --                                      
  Age                                    Mean   64   66              70                    75                               74                                                    61                                                 79                                                55                                                    75                                                    75                                                79                                                    75                                                73                                                 75                                              73                                                   73                                                     74                  74                   69                        76                             75                              75    75   67   70                                 
  SD                                     7      7    8               4                     7                                5                                                     5                                                  5                                                 5                                                     6                                                     6                                                 6                                                     6                                                 6                                                  8                                               8                                                    9                                                      7                   6                    7                         7                              7                               7     9    8                                       
  *^b^Selected*                                                                                                                                                                                                                                                                                                                                                                                    ^b^                                                                                                                                                       ^b^                                                ^b^                                             ^b^                                                  ^b^                                                                                                                                                      ^b^                             ^b^                                                
  Percentage participants showing NPMs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Apathy                                42     64   60              55                    61                               38                                                    39                                                 56                                                64                                                    87                                                    58                                                47                                                    49                                                47                                                 59                                              54                                                   66                                                     77                  88                   51                        43                             55                              64    93   45   59   38-93   1    56   43-87       
   Depression                            64     61   45              40                    70                               16                                                    45                                                 43                                                39                                                    30                                                    58                                                37                                                    32                                                39                                                 42                                              42                                                   33                                                     79                  48                   40                        46                             44                              54    75   30   44   16-79   2    39   30-46       
   Irritability                          50     64   35              5                     52                               24                                                    26                                                 19                                                24                                                    54                                                    49                                                34                                                    33                                                34                                                 27                                              25                                                   29                                                     68                  12                   39                        38                             45                              50    77   47   38   12-77   3    36   25-54       
   Agitation                             10     26   25              15                    23                               21                                                    25                                                 28                                                44                                                    34                                                    44                                                29                                                    23                                                32                                                 28                                              29                                                   33                                                     62                  44                   41                        28                             49                              64    68   35   37   21-68   4    31   23-49       
   Anxiety                               42     55   55              **15**                44                               16                                                    26                                                 28                                                38                                                    32                                                    56                                                25                                                    28                                                24                                                 39                                              39                                                   36                                                     75                  28                   41                        32                             43                              44    6    42   35   6-75    5    33   **24-43**   
   Sleep                                 10     0    15              0                     10                               7                                                     16                                                 --                                                --                                                    19                                                    57                                                --                                                    --                                                --                                                 --                                              --                                                   --                                                     28                  96                   25                        36                             47                              56    18   38   34   7-96    6    34   19-47       
   AMB                                   10     8    15              5                     0                                25                                                    22                                                 26                                                43                                                    28                                                    23                                                18                                                    16                                                20                                                 22                                              23                                                   22                                                     40                  56                   31                        --                             --                              60    20   42   28   0-60    7    21   16-28       
   Delusions                             25     17   --              --                    32                               7                                                     23                                                 13                                                50                                                    23                                                    17                                                22                                                    17                                                25                                                 27                                              28                                                   27                                                     11                  28                   22                        19                             43                              58    9    27   25   7-58    8    26   17-43       
   Apetite                               3      0    20              20                                                     20                                                    25                                                 --                                                --                                                    6                                                     53                                                --                                                    --                                                --                                                 --                                              --                                                   --                                                     21                  4                    19                        30                             40                              52    0    27   24   0-53    9    25   6-40        
   Hallucinations                        10     8    --              --                    12                               2                                                     5                                                  4                                                 22                                                    6                                                     14                                                15                                                    16                                                15                                                 22                                              19                                                   13                                                     13                  36                   12                        13                             34                              58    2    17   16   2-58    10   17   6-34        
   Disinhibition                         21     14   10              0                     12                               11                                                    5                                                  4                                                 16                                                    13                                                    0                                                 14                                                    18                                                12                                                 15                                              11                                                   9                                                      17                  0                    9                         13                             32                              32    45   30   15   0-45    11   16   11-32       
   Euphoria                              7      0    5               0                     3                                2                                                     2                                                  8                                                 7                                                     2                                                     4                                                 5                                                     4                                                 6                                                  11                                              15                                                   7                                                      9                   48                   4                         5                              9                               16    6    6    8    2-48    12   7    2-15        

Abbreviations: AMB, abnormal motor behavior; PCA, posterior cortical atrophy; AD, Alzheimer disease; SD, standard deviation; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; CDR, clinical dementia rating; NPS, neuropsychiatric symptoms.

^a^In both PCA studies, the 4 most commonly observed NPS were apathy, depression, irritability, and anxiety (highlighted in gray). Across previous AD studies, apathy, depression, and irritability were also the 3 most commonly observed, with agitation marginally more common than anxiety. The percentage of anxiety in the Isella et al^[@bibr18-0891988715606229]^ AD control group (highlighted in bold), who were significantly older than the corresponding patients with PCA, was unusually low and outside the range (also highlighted in bold) detected for previous studies involving patients with AD of comparable disease severity (estimated from MMSE/CDR score) and age (selected studies marked with^b^).

^c^Mild AD, MMSE (21-26).

^d^Moderate AD, MMSE (11-20).

^e^Severe AD, MMSE ≤ 10.

To our knowledge, there has only been 1 previous study evaluating NPS in PCA. Using the NPI, Isella et al^[@bibr18-0891988715606229]^ compared 20 PCA and 20 patients with typical AD and reported higher rates of anxiety in PCA than in the AD group. The authors concluded that anxiety seems to be particularly common in PCA. As in Isella et al,^[@bibr18-0891988715606229]^ in the present study, the 4 most common neuropsychiatric features in PCA are depression, irritability, apathy, and anxiety. However, unlike Isella et al^[@bibr18-0891988715606229]^ who reported significantly higher rates of anxiety in their PCA (55%) than AD (15%) samples, we found no significant differences in anxiety (42% vs 55%, respectively) or any other NPS between our PCA and AD groups. One possible reason for this difference is that our PCA and AD groups were matched for age, unlike those in Isella et al study. Additionally, in Isella et al sample, the anxiety rate for patients with AD is unusually low in comparison to previous studies of NPS in AD, especially for those matched to the age and disease severity characteristics of the Isella et al group (see [Table 2](#table2-0891988715606229){ref-type="table"}). The trend toward lower levels of apathy in the PCA group is consistent with findings described by Shakespeare et al,^[@bibr14-0891988715606229]^ suggesting that patients with PCA may experience less apathy than individuals with AD. On the other hand, it has recently been claimed that individuals with early-onset AD exhibit significantly more anxiety symptoms than individuals with late-onset AD.^[@bibr32-0891988715606229]^ Consistent with this claim, anxiety in the early-onset AD group was significantly more frequent than in the late-onset AD. Future studies using larger samples may determine whether this effect of age of onset upon anxiety symptoms holds true for patients with atypical AD phenotypes. Similarly, poor performance in naming tasks seems to be related to the appearance of higher rates of delusions and agitation. However, this finding needs to be replicated in larger longitudinal samples in order to ascertain the role of cognitive performance as potential predictors of psychiatric worsening.

Hallucinations and Delusions {#section5-0891988715606229}
----------------------------

Visual hallucinations have been reported in up to 25% of patients with PCA, although this proportion varies among studies. In the current sample, 3 (10%) patients presented with VH and met diagnostic criteria for DLB. These 3 cases presented features of Balint syndrome and occipital lobe atrophy on magnetic resonance imaging, and the presence of VH in these cases was not early but occurred at least 4 years after symptom onset. The presence of NPS was recorded within 6 months of the time of the SPECT. McMonagle et al^[@bibr10-0891988715606229]^ reported 6 patients with VH, 5 of them were diagnosed with DLB. In the study of Tang-Wai et al,^[@bibr6-0891988715606229]^ 2 cases developed VH within 3 to 7 years, and coexisting Lewy body disease was found on autopsy assessment. In the series of Josephs et al,^[@bibr7-0891988715606229]^ a quarter of the patients with PCA were found to have VH, and all of them met the clinical criteria for probable DLB. Moreover, AH have previously been reported as very specific of DLB and usually accompanying VH.^[@bibr21-0891988715606229],[@bibr22-0891988715606229]^ Our results are mainly in line with these previous findings, suggesting that patients with PCA and VH, especially in the presence of AH, are likely to have DLB which might be of diagnostic relevance, as treatment approaches and prognosis for DLB differ from those for AD.

Strengths and Limitations {#section6-0891988715606229}
-------------------------

The main strengths of our study are the relatively large sample size and the availability of a routinely completed questionnaire to systematically evaluate NPS in both groups of patients. A further potential limitation may arise from the fact that only presence/absence of NPS has been considered in the present study. The frequency and severity with which these symptoms emerge might constitute a difference between patients with PCA which should be addressed in future studies. One difference between this and the previous study of NPS in PCA is the inclusion of individuals diagnosed with DLB. These individuals were retained in the current analysis, as our intention was to investigate the neuropsychiatric profile of the PCA syndrome not merely those individuals with PCA attributable to probable AD.

In summary, studies approaching NPS in PCA are scarce, and further efforts should be made in this direction. Future research looking at the frequency and severity of NPS and their course over time may contribute to shed light on the neuropsychiatric profile of PCA.
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